MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Testagen Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Testagen is a Khavinson tetrapeptide bioregulator (Lys-Glu-Asp-Gly, KEDG) isolated as the synthetic analog of the active fragment from bovine prostate tissue extracts at the St. Petersburg Institute of Bioregulation and Gerontology. The cytomedin model proposes that KEDG translocates to the nuclei of prostate epithelial and Leydig cells where it complementarily binds short promoter sequences, upregulating androgen receptor expression, steroidogenic acute regulatory protein (StAR), and CYP17A1 transcription. Russian preclinical and small clinical observations describe normalization of prostate-specific antigen, improvements in International Prostate Symptom Score, and modest increases in serum testosterone in aging men. Researchers study it for benign prostatic hyperplasia, age-related androgen decline, and chronic non-bacterial prostatitis. Mechanistic context is provided by Khavinson's broader bioregulator framework (PMID 21626751) and tissue-specific transcription work (PMID 31398811).
Reconstitute: Add 3 mL bacteriostatic water → 6.67 mg/mL concentration.
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL = 0.0667 mg (67 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Plasma half-life: Not formally characterized; like other Khavinson tripeptides and tetrapeptides, KEDG is rapidly hydrolyzed in plasma with the proposed bioactive mechanism requiring only trace intact peptide reaching target nuclei.
Typical cycle: 20 to 30 day oral course at approximately 200 mcg per dose once or twice daily, repeated every 4 to 6 months, often stacked with Endoluten or Vladonix in Russian anti-aging protocols.
Regulatory status: Not approved by FDA, EMA, or other major regulators. Sold in Russia as a peptide bioregulator dietary product; no Western RCT evidence supports prostate or testicular indications.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake)[5].
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Interactive Testagen Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 3mL water yields 6.67 mg/mL. To evaluate a 250mcg dose, pull to 3.8 units (4 syringe ticks).
U-100 Syringe Representation
3.8 Units (4 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.1 mg) | 1.5 units (0.015 mL) |
| Weeks 3–4 | 150 mcg (0.15 mg) | 2.25 units (0.0225 mL) |
| Weeks 5–8 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 9–12 (optional) | 250–300 mcg (0.25–0.3 mg) | 3.75–4.5 units (0.0375–0.045 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Testagen, 20 mg each):
- check8 weeks (~14 mg used) ≈ 1 vial
- check12 weeks (~25 mg used) ≈ 2 vials
- check16 weeks (~36 mg used) ≈ 2 vials
Insulin Syringes (30‑ or 50‑unit recommended for low‑volume accuracy):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- check12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- check16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
Testagen consists of the linear tetrapeptide Lys-Glu-Asp-Gly. Within the Khavinson cytogen framework, the peptide is proposed to cross the gastrointestinal epithelium intact at low absorption efficiency, distribute to androgen-responsive tissues including the testes and prostate, and translocate into the nucleus where it forms sequence-specific hydrogen bonds with short promoter motifs in the DNA double helix [3][5]. Because the testes contain the highest steady-state expression of steroidogenic enzymes such as cholesterol side-chain cleavage enzyme (CYP11A1), 17alpha-hydroxylase/17,20-lyase (CYP17A1), and 17beta-hydroxysteroid dehydrogenase, even modest upregulation of these transcripts could increase intratesticular testosterone production. Khavinson's group has reported in cultured Leydig and Sertoli cells that KEDG application increases mRNA expression of steroidogenic acute regulatory protein (StAR) and the LH receptor, consistent with priming of testosterone biosynthesis [4]. The peptide is hydrolyzed rapidly by intestinal and serum peptidases, so its conventional pharmacokinetic profile is limited; the mechanistic model relies on a small fraction of intact peptide reaching the nucleus and exerting catalytic transcriptional effects. The standard research route is oral capsules; injectable cytogen formulations are described in Russian clinical practice but are not standardized internationally. Studies typically use 200 to 400 mcg twice daily for 20 to 30 days, with cycles repeated every 4 to 6 months. Common research applications include early-stage hypogonadism in aging men, chronic abacterial prostatitis with associated low testosterone, post-cycle support in androgen-using cohorts, and general anti-aging stacks targeting the hypothalamic-pituitary-gonadal axis. Reported downstream effects include modest increases in total and free testosterone in older male cohorts (typically 10 to 30 percent above baseline), improvements in International Index of Erectile Function (IIEF) scores, decreased oxidative stress markers in seminal plasma, and improvements in sperm motility on follow-up semen analysis. Because the peptide is hypothesized to upregulate the gonadal response to gonadotropins rather than to directly substitute for them, the proposed mechanism would not suppress endogenous LH and FSH the way exogenous testosterone replacement does, which is the conceptual rationale for its use in fertility-preserving androgen support protocols. Importantly, no Western-grade randomized controlled trials have replicated these claims, and the bulk of evidence is Russian observational or preclinical. Cycling discipline (20 to 30 days on, 4 to 6 months off) is intended to avoid presumed receptor desensitization and to permit interim laboratory monitoring of testosterone, estradiol, LH, FSH, and PSA. Stacking with other Khavinson cytogens such as Prostamax (prostate), Endoluten (pineal), and Cerluten (brain) is common in anti-aging research protocols on the rationale that simultaneous tissue-specific modulation across multiple organ systems can compound the proposed gene-reactivation effect, although no formal pharmacokinetic or pharmacodynamic interaction studies among Khavinson peptides have been published. Russian longitudinal cohort observations using multi-peptide stacks have reported reductions in functional age estimates of 1 to 2 years over 6 to 12 months of cycled use, but these observations lack blinding, control comparators, and standardized endpoint definitions. As with all Khavinson bioregulators, the absence of FDA-grade toxicology dossiers, good-laboratory-practice safety pharmacology, and modern drug-interaction studies means that the safety claim relies on observational use rather than rigorous controlled data.
Clinical Trial Efficacy Highlights
- starIn rat models of chronic abacterial prostatitis, oral administration of KEDG for 20 days reduced histological signs of inflammation, decreased stromal edema, and partially restored testicular testosterone synthesis as measured by intratesticular hormone assay [4].
- starKhavinson and colleagues have reported in cultured Leydig cells that KEDG increases expression of StAR protein and LH receptor mRNA, providing a mechanistic basis for the proposed steroidogenic effect [2][4].
- starA small open-label Russian study in men aged 60 to 75 with age-related decline in androgen production observed a modest increase in serum total testosterone over a 30-day Testagen course, with no significant change in LH or FSH suggesting a gonadal rather than central mechanism [1].
- starIn hypophysectomized birds, Testagen-related peptides prevented thyroid and gonadal atrophy that normally follows loss of pituitary input, supporting a tissue-autonomous trophic effect independent of gonadotropins [3].
- starAnimal studies on telomerase activity in reproductive tissues have suggested that Khavinson peptides including Testagen-class compounds increase telomerase mRNA expression in primary fibroblasts, consistent with the broader anti-senescence claims of the bioregulator program [5][6].
- starKhavinson's longitudinal cohort observations in elderly cohorts using multi-peptide stacks (Testagen plus Prostamax plus Endoluten) reported reductions in functional age estimates of 1 to 2 years over a 6- to 12-month follow-up, although these observations were not blinded and lacked a control comparator [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningAcross decades of Russian clinical use, Testagen has been described as essentially free of serious adverse events at standard doses, with rare reports of transient gastrointestinal upset or mild headache during the first few days of a cycle.
- warningBecause the peptide is proposed to upregulate testosterone production, individuals with hormone-sensitive conditions including prostate cancer, severe benign prostatic hyperplasia, or polycythemia should not use Testagen outside of explicit research protocols.
- warningTheoretical risk of mild estradiol elevation exists if increased testosterone is aromatized, particularly in men with high baseline adiposity; serum hormone monitoring is reasonable in extended-use research contexts.
- warningNo formal drug-interaction studies have been published; concurrent use with exogenous testosterone, selective estrogen receptor modulators (SERMs), or aromatase inhibitors would alter the expected hormonal trajectory and should be considered.
- warningUse in women and pediatric populations has not been evaluated; the peptide is intended only for adult male research subjects.
- warningBecause the peptide could theoretically activate androgen-driven gene expression in non-target tissues, individuals with a personal or family history of prostate, breast, or other hormone-dependent malignancy should avoid use.
- warningNo teratogenicity or reproductive toxicity studies have been published; effects on partners' fertility are unknown and concurrent use during fertility treatment cycles should be discussed with a reproductive endocrinologist.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Testagen dosage?expand_more
Standard Khavinson protocols use 1 to 2 oral capsules (approximately 200 mcg KEDG per capsule) twice daily for a 20- to 30-day course, repeated every 4 to 6 months. Higher doses have not been formally evaluated and no parenteral dose-response curve has been published in Western journals.
How is Testagen used in research protocols?expand_more
Research applications focus on age-related hypogonadism, chronic abacterial prostatitis with low testosterone, and fertility-preserving androgen support. Endpoints typically include serum total and free testosterone, LH, FSH, IIEF scores, and semen analysis parameters.
Can Testagen be combined with other peptides?expand_more
Testagen is frequently stacked with Prostamax (prostate), Endoluten (pineal/melatonin axis), and Cerluten (brain) in the Khavinson bioregulator framework. Combinations with mainstream hypogonadism therapies such as clomiphene or enclomiphene have not been formally studied.
What are the side effects of Testagen?expand_more
Published Russian experience describes minimal adverse events at standard doses. Theoretical risks include hormone-sensitive tissue stimulation, mild estradiol elevation if aromatization is robust, and unknown interactions with concurrent androgen-modulating therapies.
Is Testagen FDA approved?expand_more
No. Testagen is not approved by the FDA, EMA, or other major Western regulators and is not authorized as a drug or dietary supplement. It is used exclusively in research contexts and in Russian clinical practice under physician supervision.
Academic References & Study Citations
Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. View Scientific Paper →
Khavinson VK, Lin'kova NS, Pendina AA, et al. Effect of peptides on gene expression and protein synthesis in cell cultures. Bull Exp Biol Med. 2012;153(1):148-151. View Scientific Paper →
Khavinson VK. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. View Scientific Paper →
Anisimov VN, Khavinson VK, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci. 1994;719:483-493. View Scientific Paper →
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. View Scientific Paper →
Korkushko OV, Khavinson VK, Shatilo VB. Peptide preparations Thymalin, Cortexin, Epithalamin, and Prostatilen in correction of accelerated aging. Bull Exp Biol Med. 2011;151(3):360-365. View Scientific Paper →
Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinol Lett. 2001;22(4):251-254. View Scientific Paper →
Khavinson VK, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2014;4(2):85-92. View Scientific Paper →